샘플 요청 목록

 카트 문의
시장보고서
상품코드
1637054

거담제 시장 - 세계 업계 분석, 규모, 점유율, 성장, 동향, 예측(2032년)

Expectorant Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032
발행일: | 리서치사: Fairfield Market Research | 페이지 정보: 영문 178 Pages | 배송안내 : 2-5일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 거담제 시장은 호흡기질환의 유병률 증가와 효과적인 증상 관리에 대한 인식이 높아짐에 따라 CAGR 4.20%(연평균 4.00%)로 성장하여 2025년에는 182억 4,000만 달러, 2032년에는 243억 2,000만 달러에 달할 것으로 예상됩니다. 000만 달러에 달할 것으로 예상됩니다. 거담제는 만성폐쇄성폐질환(COPD), 천식, 기관지염 등의 증상을 앓고 있는 환자의 점액 배출을 촉진하고 호흡의 편안함을 향상시키는 등 호흡기 건강관리에서 매우 중요한 역할을 합니다.

거담제는 기도에서 점액 배출을 촉진하여 호흡기질환 관리에 필수적인 역할을 합니다. 기침과 코막힘을 완화하는 효과가 있어 만성 및 급성 호흡기 치료에 필수적입니다. 이 시장의 성장 궤적은 약물 제형의 지속적인 혁신과 첨단 약물전달 메커니즘의 통합에 의해 뒷받침되고 있습니다.

COPD, 천식 등 만성질환이 점점 더 흔해지면서 거담제 수요를 견인하고 있습니다. 호흡기 건강이 전 세계적으로 우선순위로 떠오르면서 이러한 약물은 증상 관리의 중요한 부분으로 자리 잡고 있습니다. 조기 및 효과적인 증상 관리의 이점에 대한 인식이 높아짐에 따라 시장 성장을 촉진하고 있습니다. 예방 의료 관행은 합병증을 피하기 위해 적시에 거담제를 사용하는 것을 강조하고 있습니다. 제약회사들은 혁신적인 거담제 개발에 많은 투자를 하고 있으며, 이는 시장의 잠재력을 더욱 높이고 있습니다.

세계의 거담제 시장에 대해 조사했으며, 시장 개요와 함께 약제 종류별, 제형별, 제품 종류별, 유통 채널별, 지역별 동향, 시장 진입 기업의 경쟁 동향 등의 정보를 전해드립니다.

목차

제1장 주요 요약

제2장 시장 개요

  • 시장 정의와 세분화
  • 시장 역학
  • 밸류체인 분석
  • Porter's Five Forces 분석
  • COVID-19의 영향 분석
  • PESTLE 분석

제3장 2025년 가격 분석

제4장 세계의 거담제 시장 전망, 2019-2032년

  • 세계의 거담제 시장 전망, 약물 유형별, 금액(10억 달러), 수량(100만 개), 2019-2032년
  • 세계의 거담제 시장 전망, 제형별, 금액(10억 달러), 수량(100만 개), 2019-2032년
  • 세계의 거담제 시장 전망, 제품 유형별, 금액(10억 달러), 수량(100만 개), 2019-2032년
  • 세계의 거담제 시장 전망, 유통 채널별, 금액(10억 달러), 수량(100만 개), 2019-2032년
  • 세계의 거담제 시장 전망, 지역별, 금액(10억 달러), 수량(100만 개), 2019-2032년

제5장 북미의 거담제 시장 전망, 2019-2032년

제6장 유럽의 거담제 시장 전망, 2019-2032년

제7장 아시아태평양의 거담제 시장 전망, 2019-2032년

제8장 라틴아메리카의 거담제 시장 전망, 2019-2032년

제9장 중동 및 아프리카의 거담제 시장 전망, 2019-2032년

제10장 경쟁 구도

  • 기업 시장 점유율 분석, 2025년
  • 경쟁 대시보드
  • 기업 개요
    • Abbott Laboratories
    • Acella Pharmaceuticals LLC
    • Astrazeneca Plc.
    • Cipla Limited
    • Dabur India Ltd
    • Glenmark Pharmaceuticals Limited
    • Johnson and Johnson
    • Merck KGaA
    • Novartis International AG
    • 기타

제11장 부록

KSM 25.02.11

The global expectorant drugs market is set to experience significant growth, driven by the increasing prevalence of respiratory disorders and heightened awareness regarding effective symptom management. With an anticipated expansion at a CAGR of 4.20%, the market is projected to reach USD 18.24 billion in 2025 and USD 24.32 billion by 2032. Expectorant drugs play a pivotal role in respiratory healthcare, facilitating mucus clearance and enhancing breathing comfort for patients dealing with conditions like chronic obstructive pulmonary disease (COPD), asthma, and bronchitis.

Market Insights Expectorant drugs are essential in managing respiratory ailments by promoting the expulsion of mucus from the respiratory tract. Their efficacy in alleviating coughs and congestion makes them indispensable in both chronic and acute respiratory care. The market's growth trajectory is bolstered by continuous innovation in drug formulations and the integration of advanced drug delivery mechanisms.

Key Market Drivers

  • 1. Rising Prevalence of Respiratory Disorders: Chronic conditions like COPD and asthma are increasingly common, driving demand for expectorant drugs. With respiratory health gaining priority globally, these medications are becoming a critical part of symptom management.
  • 2. Awareness of Early Intervention: Growing recognition of the benefits of early and effective symptom management is propelling market growth. Preventive healthcare practices emphasize the timely use of expectorant drugs to avoid complications.
  • 3. Research and Development Advancements: Pharmaceutical companies are investing heavily in the development of innovative expectorant formulations, further enhancing the market's potential.

Business Opportunities

  • 1. Innovative Formulations and Combination Therapies: The development of advanced drug delivery systems, such as extended-release formulations, offers promising revenue opportunities. Combination therapies incorporating expectorants with bronchodilators or anti-inflammatory agents can address multiple aspects of respiratory conditions.
  • 2. Targeted Products for Diverse Demographics: Companies can expand their product portfolios by developing specialized expectorant drugs tailored for pediatric, geriatric, and condition-specific needs. This diversification addresses a broader range of patient requirements and fosters market penetration.
  • 3. Expansion into Emerging Markets: Rapid urbanization and increasing healthcare awareness in regions like South Asia and the Pacific present lucrative opportunities for market growth.

Regional Analysis

  • 1. Europe: Europe holds a dominant position in the expectorant drugs market due to its robust healthcare infrastructure and high prevalence of respiratory disorders. Advanced medical facilities and proactive respiratory health management contribute to the region's strong foothold.
  • 2. South Asia and the Pacific: This region is anticipated to witness the fastest growth, driven by urbanization, environmental challenges, and an increasing burden of respiratory ailments. Enhanced healthcare access and rising awareness further support market expansion.
  • 3. North America and East Asia: These regions also show significant market potential, attributed to established pharmaceutical industries and growing healthcare expenditure.

Key Players The expectorant drugs market is characterized by intense competition among leading pharmaceutical companies. Notable players include:

  • Abbott Laboratories
  • Acella Pharmaceuticals LLC
  • AstraZeneca Plc.
  • Cipla Limited
  • Dabur India Ltd
  • Glenmark Pharmaceuticals Limited
  • Johnson & Johnson
  • Merck KGaA
  • Novartis International AG
  • Pfizer Inc.
  • Procter & Gamble Co.

These companies focus on strategic partnerships, innovative product launches, and geographical expansion to strengthen their market position.

Recent Developments

1. Product Launches:

    In October 2023, Efficient Laboratories introduced "ROMPR PECHITO," an OTC medicine designed for pediatric cold relief. In September 2023, Genexa launched new clean OTC kids' medicines, emphasizing safety and effectiveness, which resonated well with health-conscious consumers.

Market SegmentationThe expectorant drugs market can be categorized as follows:

1. By Drug Type:

    Secretion Enhancers: Includes potassium citrate, guaiphenesin, and ammonium chloride. Mucolytics: Comprising bromhexine, ambroxol, and acetyl cysteine.

2. By Dosage Form:

    Oral Solid: Tablets and capsules dominate due to patient convenience and precise dosing. Oral Liquid: Fast-acting formulations gaining popularity for rapid symptom relief. Inhalants: Preferred for targeted respiratory treatment.

3. By Product Type:

    Over-The-Counter (OTC): Leading segment due to accessibility and ease of use. Prescription Drugs: Essential for managing complex respiratory conditions.

4. By Distribution Channel:

    Hospital Pharmacies: Highest sales due to direct integration with healthcare facilities. Online Pharmacies: Fastest-growing segment, driven by digital convenience and accessibility. Retail Stores and Drug Stores: Continues to be a critical distribution channel.

5. By Region:

    North America Europe East Asia South Asia & Oceania Latin America Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Expectorant Drugs Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value and Volume, 2025
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. PESTLE Analysis

3. Price Analysis, 2025

  • 3.1. Global Average Price Analysis, by Drug Type/ Material, US$ Per Unit, 2025
  • 3.2. Prominent Factor Affecting Expectorant Drugs Prices
  • 3.3. Global Average Price Analysis, by Region, US$ Per Unit

4. Global Expectorant Drugs Market Outlook, 2019 - 2032

  • 4.1. Global Expectorant Drugs Market Outlook, by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 4.1.1. Key Highlights
      • 4.1.1.1. Secretion Enhancer
        • 4.1.1.1.1. Potassium Citrate
        • 4.1.1.1.2. Potassium Iodide
        • 4.1.1.1.3. Sodium Citrate
        • 4.1.1.1.4. Guaiphenesin
        • 4.1.1.1.5. Ammonium Chloride
        • 4.1.1.1.6. Others
      • 4.1.1.2. Mucolytics
        • 4.1.1.2.1. Bromhexine
        • 4.1.1.2.2. Ambroxol
        • 4.1.1.2.3. Acetyl Cysteine
        • 4.1.1.2.4. Carbocisteineurine
  • 4.2. Global Expectorant Drugs Market Outlook, by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 4.2.1. Key Highlights
      • 4.2.1.1. Oral Solid
      • 4.2.1.2. Oral Liquid
      • 4.2.1.3. Inhalant
  • 4.3. Global Expectorant Drugs Market Outlook, by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 4.3.1. Key Highlights
      • 4.3.1.1. Over The Counter (OTC)
      • 4.3.1.2. Prescription Drug
  • 4.4. Global Expectorant Drugs Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 4.4.1. Key Highlights
      • 4.4.1.1. Hospital Pharmacies
      • 4.4.1.2. Retail Store
      • 4.4.1.3. Drug Store
      • 4.4.1.4. Online Pharmacies
  • 4.5. Global Expectorant Drugs Market Outlook, by Region, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 4.5.1. Key Highlights
      • 4.5.1.1. North America
      • 4.5.1.2. Europe
      • 4.5.1.3. Asia Pacific
      • 4.5.1.4. Latin America
      • 4.5.1.5. Middle East & Africa

5. North America Expectorant Drugs Market Outlook, 2019 - 2032

  • 5.1. North America Expectorant Drugs Market Outlook, by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.1.1. Key Highlights
      • 5.1.1.1. Secretion Enhancer
        • 5.1.1.1.1. Potassium Citrate
        • 5.1.1.1.2. Potassium Iodide
        • 5.1.1.1.3. Sodium Citrate
        • 5.1.1.1.4. Guaiphenesin
        • 5.1.1.1.5. Ammonium Chloride
        • 5.1.1.1.6. Others
      • 5.1.1.2. Mucolytics
        • 5.1.1.2.1. Bromhexine
        • 5.1.1.2.2. Ambroxol
        • 5.1.1.2.3. Acetyl Cysteine
        • 5.1.1.2.4. Carbocisteineurine
  • 5.2. North America Expectorant Drugs Market Outlook, by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.2.1. Key Highlights
      • 5.2.1.1. Oral Solid
      • 5.2.1.2. Oral Liquid
      • 5.2.1.3. Inhalant
  • 5.3. North America Expectorant Drugs Market Outlook, by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.3.1. Key Highlights
      • 5.3.1.1. Over The Counter (OTC)
      • 5.3.1.2. Prescription Drug
  • 5.4. North America Expectorant Drugs Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.4.1. Key Highlights
      • 5.4.1.1. Hospital Pharmacies
      • 5.4.1.2. Retail Store
      • 5.4.1.3. Drug Store
      • 5.4.1.4. Online Pharmacies
  • 5.5. North America Expectorant Drugs Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.5.1. Key Highlights
      • 5.5.1.1. Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 5.5.1.2. Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 5.5.1.3. Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 5.5.1.4. Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 5.5.1.5. Canada Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 5.5.1.6. Canada Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 5.5.1.7. Canada Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 5.5.1.8. Canada Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Europe Expectorant Drugs Market Outlook, 2019 - 2032

  • 6.1. Europe Expectorant Drugs Market Outlook, by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.1.1. Key Highlights
      • 6.1.1.1. Secretion Enhancer
        • 6.1.1.1.1. Potassium Citrate
        • 6.1.1.1.2. Potassium Iodide
        • 6.1.1.1.3. Sodium Citrate
        • 6.1.1.1.4. Guaiphenesin
        • 6.1.1.1.5. Ammonium Chloride
        • 6.1.1.1.6. Others
      • 6.1.1.2. Mucolytics
        • 6.1.1.2.1. Bromhexine
        • 6.1.1.2.2. Ambroxol
        • 6.1.1.2.3. Acetyl Cysteine
        • 6.1.1.2.4. Carbocisteineurine
  • 6.2. Europe Expectorant Drugs Market Outlook, by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.2.1. Key Highlights
      • 6.2.1.1. Oral Solid
      • 6.2.1.2. Oral Liquid
      • 6.2.1.3. Inhalant
  • 6.3. Europe Expectorant Drugs Market Outlook, by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.3.1. Key Highlights
      • 6.3.1.1. Over The Counter (OTC)
      • 6.3.1.2. Prescription Drug
  • 6.4. Europe Expectorant Drugs Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.4.1.1. Hospital Pharmacies
      • 6.4.1.2. Retail Store
      • 6.4.1.3. Drug Store
      • 6.4.1.4. Online Pharmacies
  • 6.5. Europe Expectorant Drugs Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.5.1. Key Highlights
      • 6.5.1.1. Germany Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.2. Germany Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.3. Germany Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.4. Germany Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.5. U.K. Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.6. U.K. Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.7. U.K. Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.8. U.K. Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.9. France Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.10. France Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.11. France Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.12. France Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.13. Italy Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.14. Italy Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.15. Italy Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.16. Italy Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.17. Turkey Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.18. Turkey Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.19. Turkey Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.20. Turkey Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.21. Russia Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.22. Russia Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.23. Russia Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.24. Russia Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.25. Rest of Europe Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.26. Rest of Europe Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.27. Rest of Europe Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.28. Rest of Europe Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Asia Pacific Expectorant Drugs Market Outlook, 2019 - 2032

  • 7.1. Asia Pacific Expectorant Drugs Market Outlook, by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.1.1. Key Highlights
      • 7.1.1.1. Secretion Enhancer
        • 7.1.1.1.1. Potassium Citrate
        • 7.1.1.1.2. Potassium Iodide
        • 7.1.1.1.3. Sodium Citrate
        • 7.1.1.1.4. Guaiphenesin
        • 7.1.1.1.5. Ammonium Chloride
        • 7.1.1.1.6. Others
      • 7.1.1.2. Mucolytics
        • 7.1.1.2.1. Bromhexine
        • 7.1.1.2.2. Ambroxol
        • 7.1.1.2.3. Acetyl Cysteine
        • 7.1.1.2.4. Carbocisteineurine
  • 7.2. Asia Pacific Expectorant Drugs Market Outlook, by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.2.1. Key Highlights
      • 7.2.1.1. Oral Solid
      • 7.2.1.2. Oral Liquid
      • 7.2.1.3. Inhalant
  • 7.3. Asia Pacific Expectorant Drugs Market Outlook, by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.3.1. Key Highlights
      • 7.3.1.1. Over The Counter (OTC)
      • 7.3.1.2. Prescription Drug
  • 7.4. Asia Pacific Expectorant Drugs Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.4.1. Key Highlights
      • 7.4.1.1. Hospital Pharmacies
      • 7.4.1.2. Retail Store
      • 7.4.1.3. Drug Store
      • 7.4.1.4. Online Pharmacies
  • 7.5. Asia Pacific Expectorant Drugs Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.5.1. Key Highlights
      • 7.5.1.1. China Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.2. China Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.3. China Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.4. China Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.5. Japan Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.6. Japan Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.7. Japan Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.8. Japan Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.9. South Korea Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.10. South Korea Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.11. South Korea Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.12. South Korea Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.13. India Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.14. India Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.15. India Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.16. India Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.17. Southeast Asia Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.18. Southeast Asia Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.19. Southeast Asia Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.20. Southeast Asia Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.21. Rest of Asia Pacific Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.22. Rest of Asia Pacific Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.23. Rest of Asia Pacific Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.24. Rest of Asia Pacific Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Latin America Expectorant Drugs Market Outlook, 2019 - 2032

  • 8.1. Latin America Expectorant Drugs Market Outlook, by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.1.1. Key Highlights
      • 8.1.1.1. Secretion Enhancer
        • 8.1.1.1.1. Potassium Citrate
        • 8.1.1.1.2. Potassium Iodide
        • 8.1.1.1.3. Sodium Citrate
        • 8.1.1.1.4. Guaiphenesin
        • 8.1.1.1.5. Ammonium Chloride
        • 8.1.1.1.6. Others
      • 8.1.1.2. Mucolytics
        • 8.1.1.2.1. Bromhexine
        • 8.1.1.2.2. Ambroxol
        • 8.1.1.2.3. Acetyl Cysteine
        • 8.1.1.2.4. Carbocisteineurine
  • 8.2. Latin America Expectorant Drugs Market Outlook, by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.2.1.1. Oral Solid
      • 8.2.1.2. Oral Liquid
      • 8.2.1.3. Inhalant
  • 8.3. Latin America Expectorant Drugs Market Outlook, by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.3.1. Key Highlights
      • 8.3.1.1. Over The Counter (OTC)
      • 8.3.1.2. Prescription Drug
  • 8.4. Latin America Expectorant Drugs Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.4.1. Key Highlights
      • 8.4.1.1. Hospital Pharmacies
      • 8.4.1.2. Retail Store
      • 8.4.1.3. Drug Store
      • 8.4.1.4. Online Pharmacies
  • 8.5. Latin America Expectorant Drugs Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.5.1. Key Highlights
      • 8.5.1.1. Brazil Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.2. Brazil Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.3. Brazil Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.4. Brazil Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.5. Mexico Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.6. Mexico Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.7. Mexico Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.8. Mexico Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.9. Argentina Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.10. Argentina Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.11. Argentina Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.12. Argentina Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.13. Rest of Latin America Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.14. Rest of Latin America Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.15. Rest of Latin America Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.16. Rest of Latin America Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Middle East & Africa Expectorant Drugs Market Outlook, 2019 - 2032

  • 9.1. Middle East & Africa Expectorant Drugs Market Outlook, by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.1.1. Key Highlights
      • 9.1.1.1. Secretion Enhancer
        • 9.1.1.1.1. Potassium Citrate
        • 9.1.1.1.2. Potassium Iodide
        • 9.1.1.1.3. Sodium Citrate
        • 9.1.1.1.4. Guaiphenesin
        • 9.1.1.1.5. Ammonium Chloride
        • 9.1.1.1.6. Others
      • 9.1.1.2. Mucolytics
        • 9.1.1.2.1. Bromhexine
        • 9.1.1.2.2. Ambroxol
        • 9.1.1.2.3. Acetyl Cysteine
        • 9.1.1.2.4. Carbocisteineurine
  • 9.2. Middle East & Africa Expectorant Drugs Market Outlook, by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.2.1. Key Highlights
      • 9.2.1.1. Oral Solid
      • 9.2.1.2. Oral Liquid
      • 9.2.1.3. Inhalant
  • 9.3. Middle East & Africa Expectorant Drugs Market Outlook, by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.3.1. Key Highlights
      • 9.3.1.1. Over The Counter (OTC)
      • 9.3.1.2. Prescription Drug
  • 9.4. Middle East & Africa Expectorant Drugs Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.4.1. Key Highlights
      • 9.4.1.1. Hospital Pharmacies
      • 9.4.1.2. Retail Store
      • 9.4.1.3. Drug Store
      • 9.4.1.4. Online Pharmacies
  • 9.5. Middle East & Africa Expectorant Drugs Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.5.1. Key Highlights
      • 9.5.1.1. GCC Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.2. GCC Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.3. GCC Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.4. GCC Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.5. South Africa Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.6. South Africa Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.7. South Africa Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.8. South Africa Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.9. Egypt Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.10. Egypt Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.11. Egypt Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.12. Egypt Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.13. Nigeria Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.14. Nigeria Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.15. Nigeria Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.16. Nigeria Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.17. Rest of Middle East & Africa Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.18. Rest of Middle East & Africa Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.19. Rest of Middle East & Africa Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.20. Rest of Middle East & Africa Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.5.2. BPS Analysis/Market Attractiveness Analysis

10. Competitive Landscape

  • 10.1. Company Market Share Analysis, 2025
  • 10.2. Competitive Dashboard
  • 10.3. Company Profiles
    • 10.3.1. Abbott Laboratories
      • 10.3.1.1. Company Overview
      • 10.3.1.2. Product Portfolio
      • 10.3.1.3. Financial Overview
      • 10.3.1.4. Business Strategies and Development
    • 10.3.2. Acella Pharmaceuticals LLC
      • 10.3.2.1. Company Overview
      • 10.3.2.2. Product Portfolio
      • 10.3.2.3. Financial Overview
      • 10.3.2.4. Business Strategies and Development
    • 10.3.3. Astrazeneca Plc.
      • 10.3.3.1. Company Overview
      • 10.3.3.2. Product Portfolio
      • 10.3.3.3. Financial Overview
      • 10.3.3.4. Business Strategies and Development
    • 10.3.4. Cipla Limited
      • 10.3.4.1. Company Overview
      • 10.3.4.2. Product Portfolio
      • 10.3.4.3. Financial Overview
      • 10.3.4.4. Business Strategies and Development
    • 10.3.5. Dabur India Ltd
      • 10.3.5.1. Company Overview
      • 10.3.5.2. Product Portfolio
      • 10.3.5.3. Financial Overview
      • 10.3.5.4. Business Strategies and Development
    • 10.3.6. Glenmark Pharmaceuticals Limited
      • 10.3.6.1. Company Overview
      • 10.3.6.2. Product Portfolio
      • 10.3.6.3. Financial Overview
      • 10.3.6.4. Business Strategies and Development
    • 10.3.7. Johnson and Johnson
      • 10.3.7.1. Company Overview
      • 10.3.7.2. Product Portfolio
      • 10.3.7.3. Financial Overview
      • 10.3.7.4. Business Strategies and Development
    • 10.3.8. Merck KGaA
      • 10.3.8.1. Company Overview
      • 10.3.8.2. Product Portfolio
      • 10.3.8.3. Financial Overview
      • 10.3.8.4. Business Strategies and Development
    • 10.3.9. Novartis International AG
      • 10.3.9.1. Company Overview
      • 10.3.9.2. Product Portfolio
      • 10.3.9.3. Financial Overview
      • 10.3.9.4. Business Strategies and Development
    • 10.3.10. Others
      • 10.3.10.1. Company Overview
      • 10.3.10.2. Product Portfolio
      • 10.3.10.3. Financial Overview
      • 10.3.10.4. Business Strategies and Development

11. Appendix

  • 11.1. Research Methodology
  • 11.2. Report Assumptions
  • 11.3. Acronyms and Abbreviations
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제